Promising New HIV Vaccine Clinical Trial to Launch in South Africa

Here is some good, or at least hopeful news in the midst of all this political turmoil and tragedy. The Associated Press reported on Sunday that a trial to test a new HIV vaccine will launch in South Africa on Wednesday, and scientists are cautiously optimistic about it.


The study, called HVTN 702, will be the largest HIV vaccine clinical trial ever to take place in South Africa, involving 5,400 sexually active men and women between the ages of 18 and 35.

More than 1,000 people are infected with HIV every day in South Africa, and there are some 6.8 million people living with HIV in the country.

Anthony Fauci, director of the United States’ National Institute of Allergy and Infectious Diseases, which has funded the trial, said in a press release, “If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV,” adding that, “Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa.”

Glenda Gray, chief executive officer of the South African Medical Research Council told the AP, “HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country.”

HVTN 702 is a moderated version of a vaccine that was found in a 2009 trial in Thailand to be 31.2 percent effective at preventing HIV infection over the course of a 3.5-year follow-up period.

The study is excepted to yield results in 2020, according to the AP.

[Associated Press]

contributing writer, nights



Just to put that 31.2 in context, last year’s flu vaccine was found to be 47% effective, the year before was 19%.